Prescribing omissions in elderly patients admitted to a stroke unit: Descriptive study using START criteria

International Journal of Clinical Pharmacy

Volumn 34, Issue 3, 2012, Pages 481-489

  Borges, Elisabete Pinto ^a   Morgado, Manuel ^b   MacEdo, Ana Filipa ^b  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Adverse drug reaction; Cardiovascular disease; Drug prescriptions; Elderly; Portugal; START criteria; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

AGED; ARTICLE; BRAIN DISEASE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DESCRIPTIVE RESEARCH; DIABETES MELLITUS; DRUG INFORMATION; ELDERLY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION ERROR; MICROALBUMINURIA; PERIPHERAL VASCULAR DISEASE; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK MANAGEMENT; SCREENING TEST; SCREENING TOOL TO ALERT DOCTORS TO THE RIGHT TREATMENT; STABLE ANGINA PECTORIS; STROKE UNIT; TEACHING HOSPITAL; TRANSIENT ISCHEMIC ATTACK; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; DRUG PRESCRIPTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MEDICATION ERRORS; MIDDLE AGED; PATIENT ADMISSION; PHYSICIANS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84862993351     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9635-1     Document Type: Article

References (47)

1. Hashimoto K, Tabata K. Population aging, health care and growth. J Popul Econ. 2010;23:571-93.
2. Preventing Chronic Diseases. A Vital Investment: WHO Global Report. Geneva: World Health Organization, 2005. pp 200.
3. CHF 30.00. ISBN 92 4 1563001. Int J Epidemiol. 2006; 35(4):1107.
4. Instituto Nacional de Estatística, Revista de Estudos Demográfi-cos, no 46, Novembro 2009; [on-line] Available at URL: http://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine-publicacoes& PUBLICACOESpub-boui=81528281&PUBLICACOEStema= 55466&PUBLICACOESmodo=2). Accessed on Jan 2012, ISSN 1645-5657.
5. Hajjar ER, Cafiero AC, Halon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-55.
6. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21(12):793-811.
7. Halon JT, Lindblad CI, Hajjar ER, McCarthy TC. Update on drug-related problems in the elderly. Am J Geriatr Pharmacother. 2003;1:38-43.
8. Wright RM, Sloane R, Pieper CF, Ruby-Scelsi C, Twersky J, Schmader KE, Hanlon JT. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother. 2009;7(5):271-80.
9. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in the elderly patients. Age Ageing. 1992;21(4):294-300.
10. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention, ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
11. Barry PJ, Gallagher P, Ryan C. Inappropriate prescribing in geriatric patients. Curr Psychiatry Rep. 2008;10:37-43.
12. Spinewine A, Schamader KE, Barbr N, Hughes C, Lapane KL, Swine C, Halon JT. Prescribing in elderly people 1 Appropriate prescribing in elderly people: how well can it be measured and optimized? Lancet. 2007;370(9582):173-84.
13. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing homes. Arch Intern Med. 1991;151(9): 1825-32.
14. Beers MH. Explicit criteria for determining potentially inappropriate medication use in elderly: an update. Arch Intern Med. 1997;157(14):1531-6.
15. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103-7.
16. Halon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, Cohen HJ, Feussner JR. A method assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045-51.
17. Wenger NS, Shekelle PG. ACOVE investigators, assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135(8):642-6.
18. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening tool of older person's prescriptions) and START (Screening tool to alert doctors to the right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72-83.
19. Barry PJ, Gallagher P, Ryan C, O'Mahony D. START (screening tool to alert doctors to the right treatment)-an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36:632-8.
20. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007, 28 (19) 2375-2414.
21. Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L, Ahmed A, Banach M. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50:114-8.
22. Guerra LC, Moreno MCF, Suero JA. Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. Eur J Intern Med. 2009;20:586-90.
23. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115(6):700-7.
24. Diamond GA, Kaul S. Prevention and treatment: a tale of two strategies. J Am Coll Cardiol. 2008;51:46-8.
25. Ryan C, O'Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936-47.
26. Kuijpers MAJ, van Marum RJ, Egberts ACG, Jansen PAF, The OLDY (OLd people Drugs & dYsregulations) study group. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2007;65(1):130-3.
27. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516-23.
28. Gallagher PF, O'Connor MN, O'Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;6:845-54.
29. Broeiro P, Maio I, Ramos V. Polifarmacoterapia Estratégias de Racionalização, Dossier: prescrição em medicina geral e familiar. Rev Port Clin Geral. 2008;24:625-31.
30. Pyszka LL, Seys Ranola TM, Milhans SM. Identification of inappropriate prescribing in geriatrics at a Veterans Affairs hospital using STOPP/START screening tools. Consult Pharm. 2010; 25(6):365-73.
31. Amarenco P, Labreuche J, Lavalle P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-9.
32. European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. Guideline for management of ischaemic stroke and transient ischaemic attack. 2008. Cerebrovasc Dis. 2008;25(5):457-507.
33. Smith SC, Allen J, Blair SN, Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease, 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-72.
34. Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients[75 years of age). An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation and Prevention. Circulation. 2002;105(14): 1735-43.
35. Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl. 2009; 11(Suppl A):A21-A25.
36. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107(1):149-58.
37. Fox K, Garcia MA, Ardissino D, Buzzman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341-81.
38. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
39. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial Hypertension. Eur Heart J. 2007;28(12):1462-536.
40. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31(4):822-7.
41. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651-745.
42. Sirois C, Moisan J, Poirier P, Grégoire J-P. Underuse of cardio-protective treatment by the elderly with type 2 diabetes. Diabetes Metab. 2008;34(2):169-76.
43. Sigal R, Malcolm J, Meggison H. Prevention of cardiovascular events in diabetes. Clin Evid. 2005;14:501-21.
44. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88-136.
45. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.
46. Moynihan R, Smith R. Too much medicine? BMJ. 2002; 324(7342):859-60.
47. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract. 2009;59(558):43-8.